Suzetrigine as the Future of Acute Pain Management: Moving Beyond Opioid-Based Therapy

Abstract

The ongoing opioid epidemic in the United States highlights the need for new anesthetics with reduced threat of abuse, dependence, and adverse central nervous system goods. Suzetrigine (trade name Journavx), a first- in- class picky Nav 1.8(a sodium channel expressed in supplemental nociceptors) asset, was approved by the FDA in early 2025 and retailed as the first non-opioid analgesic in over two decades. Current studies have shown that suzetrigine has implicit in treating acute pain perioperatively for minimally to relatively painful itinerant procedures. still, suzetrigine appears less potent than hydrocodone- acetaminophen in this environment, and it remains unclear how effective suzetrigine is in treating more severe postoperative pain. specially, all current studies are limited to short durations of treatment; farther studies will be needed to delineate suzetrigine’s long- term efficacity, safety, and dependence eventuality to be employed in the operation of habitual pain cases. This composition provides a review of the current literature available on the use of suzetrigine in treating acute pain. The medicine didn't beget respiratory depression or dependence, which distinguishes it from opioids. Ongoing pharmacokinetic studies and long- term compliances aim to further define the medicine’s safety profile and its implicit use in cases with comorbid conditions. Suzetrigine may offer an effective and safe volition to opioids in pain treatment..

Keywords

Introduction

 

 

Figure 1. Mechanism of action of suzetrigine. Suzetrigine selectively inhibits the Nav1.8 peripheral sodium channel [22]

Because NaV channels are expressed in cardiomyocytes and may have cardiovascular effects, modulation of these channels should be done carefully. Heart failure and cardiac hypertrophy may result from the overexpression of NaV1.8 mutations, which have been connected to Brugada syndrome. Low doses of lidocaine, a non-selective NaV inhibitor used to treat pain, have analgesic effects; however, higher doses raise the risk of cardiac complications because they affect other NaV subtypes, including NaV1.5, which is critical for heart function [3].

Pharmacokinetics

Suzetrigine has a long half-life of about 30 to 60 hours and is well absorbed after oral administration, allowing for once- or twice-daily dosing while maintaining plasma concentrations in the low nanomolar range needed for near-complete inhibition of NaV1.8 (IC50 in humans ≈ 0.68 nM) in clinical 2025 Mach et al. research [9,23]. Because it is mostly metabolized in the liver through glucuronidation and has little renal excretion, patients with hepatic impairment should exercise caution, while those with renal dysfunction usually don't need to adjust their dosage [9,23]. Its pharmacokinetics may differ significantly by sex, according to preclinical research, with female rats showing significantly higher systemic exposure, an area under the curve (AUC0-t) up to 50 times greater, and oral bioavailability (96 percent vs. 11 percent in males), as a result of slower metabolism through demethylation mediated by cytochrome (CYP) CYP3A2 and CYP2C11 [24]. Good oral bioavailability and stable plasma levels were confirmed by animal pharmacokinetic profiling in monkeys, and validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) techniques supported precise quantification in preclinical trials [25].Suzetrigine only affects peripheral sensory neurons, according to distribution studies, and the central nervous system does not exhibit any discernible SCN10A (NaV1.8 gene) expression [26]. The possibility of adverse effects on the central nervous system is decreased by this peripherally restricted activity. Potency varies by species, with humans and non-human primates showing the highest sensitivity. However, the extended half-life may prolong the duration of side effects and delay the attainment of steady-state, requiring careful dose titration [9,28]. Indications A balance is necessary for the effective treatment of acute pain Complications like a delayed recovery, longer hospital stays, and a lower quality of life can result from poorly managed pain [29].Inadequate management of acute pain also raises the possibility that it will develop into chronic pain, which has substantial socioeconomic consequences [30, 31]. Acute pain is currently treated using a multimodal approach that includes several drug classes, such as acetaminophen, NSAIDs, NMDA receptor antagonists, and local anesthetics [32].                                                 Opioids continue to be a mainstay in the management of moderate to severe pain, even with the availability of the aforementioned alternatives. However, side effects like sedation, respiratory depression, nausea, vomiting, constipation, and renal dysfunction are linked to their use [33]. Additionally, about 85,000 cases of opioid use disorder (OUD) occur in the USA each year as a result of opioid pain treatment [34, 35]. Because there are few effective non-opioid alternatives and a risk of relapse, managing pain in these patients continues to be a clinical challenge [34, 35]. Because preclinical and early clinical research indicates that suzetrigine selectively inhibits peripheral sodium channels to produce analgesic effects without activating opioid receptors, it has been studied as a potential remedy in this regard [36,37]. Suzetrigine may be a useful treatment for individuals with a history of substance use disorders because this mechanism is thought to reduce the risk of abuse or physical dependence when compared to opioids [38]. NaV1.8 inhibitors have the potential to offer efficient and well-tolerated analgesia in both acute and chronic pain, and selective inhibition of the voltage-gated sodium channel has emerged as a promising therapeutic approach [39,11]. Both acute postoperative pain and chronic neuropathic pain, such as pain from neuralgia, diabetes, or peripheral nerve damage, may be relieved by suzetrigine. Patients with moderate to severe pain may benefit from it due to its mechanism of action and safety profile, especially if other treatments are ineffective, poorly tolerated, or opioid use is contraindicated or carries a risk of dependence [38, 40–42].Suzetrigine differs from opioids and is a novel alternative in pain management because it selectively suppresses pain without having a widespread depressive effect on the central nervous system by blocking NaV1.8 channels [9]. However, more extensive clinical research is required to validate its effectiveness on its use in multimodal analgesia, and in pregnant or breastfeeding patients.

Efficacy

Because NaV1.8 channels are primarily expressed in primary sensory neurons and are barely present in the majority of other neuron types, they make an appealing therapeutic target for pain management [18]. In clinical trials, suzetrigine has proven to be very effective at reducing pain, and it is more potent than VX-150, another drug with a similar mode of action. Because of its special "reverse use-dependence," repeated depolarizations can lessen its inhibitory effect [18]. While re-inhibition at negative voltages is proportionate to concentration, this process happens with a time constant of about 40 milliseconds (ms), independent of drug concentration. This implies that suzetrigine exhibits a clear state-dependent inhibition by binding to NaV1.8 channels in the resting state but much less so to channels with fully activated voltage sensors [18].              NAVIGATE-1 and NAVIGATE-2 are two pivotal randomized controlled trials that were evaluated. According to the sum of pain intensity differences over 48 hours (SPID48) outcome, patients who received suzetrigine—a 100 mg loading dose followed by 50 mg every 12 hours—reported noticeably more pain relief than those who received a placebo [20]. The abdominoplasty trial's least squares mean difference (LSMD). Additionally, suzetrigine decreased pain faster than a placebo; a clinically significant reduction in the numeric pain rating scale (NPRS) was attained in two to four hours as opposed to eight hours with a placebo [20]. Suzetrigine demonstrated comparable or marginally lower efficacy when compared to low-dose opioids, such as hydrocodone/acetaminophen (HB5/APAP325), depending on the procedure; it performed better in abdominoplasty but worse in bunionectomy [20]. Additionally, a network meta-analysis showed that the analgesic effect of suzetrigine was marginally less than that of high-dose opioids and similar to that of NSAIDs [20]. With a discontinuation rate of less than 1% and fewer gastrointestinal side effects than opioids, suzetrigine was generally well tolerated [20]. Eighty-three percent of patients with moderate to severe pain rated the treatment as good, very good, or excellent on the Patient Global Assessment in a single-arm study evaluating suzetrigine's efficacy in treating acute pain of both surgical and non-surgical origin. When additional pain relief was required, participants in this study were permitted to take rescue medication, which consists of 650 mg of acetaminophen and 400 mg of ibuprofen every six hours. Notably, the high percentage of positive evaluations was constant regardless of the type of pain—82.0 percent for surgical patients and 91.2 percent for non-surgical patients—and the use of rescue drugs had no discernible impact on suzetrigine's effectiveness [21]. The medication's good tolerability profile is further supported by the fact that only 1.6% of patients stopped treatment because it was ineffective [21].

Dosage

Clinical trials in phases II and III assessed the safety and effectiveness of different dosage schedules for the management of acute postoperative pain [36,3,43]. A loading dose of 100 mg and subsequent doses of 50 mg every 12 hours for 48 hours after surgery were used in both phases. Only the high-dose group showed a significant decrease in pain intensity (SPID) over a 48-hour period when compared to the placebo group in two Phase II trials involving patients following abdominoplasty and hallux valgus correction surgery [36]. Hydrocodone plus acetaminophen or a placebo did not significantly outperform lower doses. These results were validated in two Phase III trials involving more than 2,000 participants; the high-dose regimen produced a quick and long-lasting analgesic effect that was obviously better than a placebo, but it was either equal to or marginally less effective than hydrocodone with acetaminophen [43]. The loading dose of 100 mg, followed by 50 mg every 12 hours, is currently thought to be the most effective. Preclinical research on rats and monkeys revealed no noteworthy side effects or dependence potential [9]. There were no neurobehavioral, sedative, or stimulatory effects noted. Even at doses many times higher than therapeutic levels, suzetrigine did not cause physical dependence symptoms when abruptly stopped. Even after prolonged use, no negative effects on the respiratory or cardiovascular systems, such as variations in blood pressure or electrocardiograms (ECGs), were noted. The medication showed good tolerability and a favorable safety profile in two Phase II clinical trials with patients who had acute pain after abdominoplasty (n = 303) and hallux valgus surgery (n = 274) [36]                                                                      Constipation, headache, nausea, dizziness, and puking were the most frequent side goods (≥ 10). These symptoms were mild, went down on their own or with characteristic treatment, and didn't affect in stopping treatment. Serious side goods that were unconnected to the study drug included pulmonary embolism (in the group entering an average cure of suzetrigine), laryngeal stenosis (in the hydrocodone with acetaminophen group), and cellulitis with sepsis (in the placebo group). Compared to the placebo and hydrocodone/ acetaminophen groups, the suzetrigine groups had lower treatment termination rates. A different clinical safety study vindicated that the medicine was well permitted. The most common adverse events were headache, constipation, nausea, falls, and rash; only headache affected further than 5 of actors (7.0) (28). The maturity of adverse events were mild or moderate. Only two cases (0.8) had serious adverse events reported; one had suicidal studies, and the other did not.These reactions appear to be dose-dependent and are typically mild to moderate in severity. A skin rash and mild cognitive symptoms, such as difficulty concentrating, were also reported by some patients [9]. Despite early hope, worries about proarrhythmic risk and possible neurotoxicity at higher doses emerged [9]. Suzetrigine may also cause hypersensitivity reactions, just like other sodium channel blockers, though these seem to be less common than with lamotrigine. Because of hepatic metabolism, patients with severe liver impairment should either avoid or use the medication with caution [9]. Since teratogenic risk cannot be ruled out and there is no information on suzetrigine use during pregnancy, the medication should not be used by expectant mothers until more safety information is obtained.

Drug-drug interactions

Due to its dual roles as a CYP3A4 substrate and inducer, suzetrigine may cause serious drug interactions [44, 45]. Strong CYP3A4 inhibitors, like ketoconazole, should not be used concurrently; for moderate CYP3A4 inhibitors, dose modification is advised. Grapefruit-containing products should also be avoided because they inhibit CYP3A4 [44, 45]. Suzetrigine may lessen the effectiveness of sensitive CYP3A4 substrates, such as midazolam. Hormonal contraceptives other than levonorgestrel and norethindrone must be carefully managed, and a backup nonhormonal method is advised both during treatment and for 28 days following discontinuation [44, 45]. It is still unclear how suzetrigine affects CYP3A4 substrates like buprenorphine and methadone that are used in OUD treatment [45]. To assess possible interactions between suzetrigine and other therapeutic agents, including the effects of concurrent use of the CYP450 enzyme, more pharmacokinetic studies are presently being conducted.

Advantages of suzetrigine over existing pain medications

By offering quick, clinically significant analgesia without the sedation, euphoria, and potential for addiction that come with opioid therapy, suzetrigine provides an alternative to conventional opioids for the treatment of moderate-to-severe acute pain [34,21].. Similar to hydrocodone/acetaminophen, but with better tolerability and fewer adverse events, clinical trials in postoperative settings like abdominoplasty and bunionectomy have shown significant reductions in pain intensity (SPID48 up to 48.4 percent, p < 0.001), with a median onset of relief in just two hours [34,5]. Suzetrigine is especially appropriate for patients who are at high risk of opioid dependence or adverse drug reactions because, in contrast to NSAIDs or opioids, its targeted peripheral action selectively inhibits NaV1.8 channels in dorsal root ganglia neurons, preventing pain signal transmission without causing side effects in the central nervous system [21, 46]. Additionally, its potential, lack of abuse potential, and favorable safety profile. In multimodal regimens, suzetrigine may function as a primary non-opioid agent in addition to regional anesthesia, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and muscle relaxants; however, additional research is necessary to examine the cost-risk-benefit of such an addition. There are currently concerns about the use of suzetrigine in patients with severe hepatic and renal impairment due to the paucity of data on this topic. When giving suzetrigine to complex patients, it is important to carefully consider drug interactions with other medications that either modulate or are metabolized by CY3P4A, such as antibiotics and direct oral anticoagulants [47]. This is because suzetrigine is a CY3P4A substrate and inducer.  In general, suzetrigine appears to be clinically beneficial in addressing short-term moderate postoperative pain in a limited group of healthy patients, aiming to prevent the unanticipated central side effects of opioids.Based on the current literature, determining whether suzetrigine's pain management is comparable to opioids is challenging. However, it appears unlikely to replace opioids in patients with severe pain, who may require excessive opioid doses for analgesia [47].

FUTURE PROSPECT & CONCLUSION

As the first oral, non-opioid, selective inhibitor of the NaV1.8 sodium channel, the discovery of suzetrigine represents a significant advancement in pain management. It was authorized to treat moderate-to-severe acute pain without the major drawbacks of opioid use, such as tolerance and a high risk of addiction. This finding emphasizes the potential therapeutic benefits of focusing on NaV1.8 sodium channels, which are essential for sending pain signals to peripheral pain sensing neurons. Promising outcomes in broad spectrum acute pain relief, particularly in surgical pain, have been shown in clinical trials. Its safety and effectiveness in other pain conditions, such as postoperative and diabetic neuropathic pain, are being assessed in ongoing trials. Further research is required to evaluate the impact of long-term use and its potential in different types of chronic pain, despite the impressive results regarding its efficacy, selectivity, and safety profile in acute pain management. Similar medications may be developed as a result of suzetrigine's medicinal-chemical development. In the end, suzetrigine and its analogues may open the door to a time when traditional opioid therapy is no longer necessary for the safe and efficient management of pain [5].                                               Furthermore, central side effects like sedation or respiratory depression were not linked to suzetrigine use. Suzetrigine is safe and effective for treating acute pain, according to studies, but only in ideal, relatively healthy patients undergoing a narrow range of procedures. Only a small number of studies with patients who had mild to moderate pain—mostly after surgery—are currently available in the literature. Suzetrigine's effectiveness, safety, and potential for dependence at increasing doses and in long-term pain management are unknown and need further research because these studies had brief treatment periods at a static dose. To determine whether suzetrigine is a useful adjunct in a multimodal pain regimen with or without opioids, as well as in the treatment of severe pain after more difficult, painful procedures like spine surgery or in outpatients with underlying chronic conditions, more research is necessary. suzetrigine not only reduces the burden of opioid-affiliated complications, similar as dependence, but may also offer long- term profitable advantages. While ongoing studies are demanded to further clarify long- term safety, medicine relations, and efficacity in special populations, current substantiation supports suzetrigine as a promising, safe, and effective on-opioid volition in acute pain operation- especially precious in the environment of the ongoing opioid extremity [48-51].In terms of  unborn policy, Suzetrigine will significantly  concentrate on expanding its approved uses beyond acute pain to  habitual conditions  similar as neuropathic pain and other implicit pain. This also includes habitual pain that comes from conditions similar as cancer. also, given the ongoing necessity for opioid druthers, some nonsupervisory programs may be acclimated to gormandize ? track farther exploration and blessings. Counteraccusations of this drug include reduced opioid dependence, lower overall healthcare costs, as well as wider access for cases with habitual pain operation. also, the counteraccusations may also potentially lower the need for robust post ? marketing surveillance to cover long ? term effectiveness and safety of dad tients [52]. As per the preclinical and clinical settings, suzetrigine has been proven to be a well ? permitted drug with mild adverse goods. Suzetrigine has shown a promising advancement in the treatment of acute pain treatment when it comes in the environment of the ongoing opioid extremity. still, to estimate the long ? term safety and efficacity, similar as habitual treatment or in case of effective combinational remedy, farther exploration is demanded. This oral pain drug has the implicit to come a critical tool used to reduce opioid reliance in the operation of both acute, habitual, and neuropathic pain with the expansion of clinical trials. However, this can be a corner for its clinical efficacity, therefore furnishing relief to the cases having limited treatment options, If ongoing studies on this medicine authorize its efficacity in these certain conditions. Sufficient knowledge, advocacy, and education are needed for the transition from opioid anesthetics to non ? opioid anesthetics. It is the core responsibility of the healthcare workers to be accus to med to the benefits, dosing, and other implicit goods of suzetrigine. Cases generally specified opioid anesthetics also need to be duly educated about the actuality of interchangeable non ? opioid druthers. Incipiently, to authenticate the tolerability and effectiveness of this drug, data from clinical trials, rather of data (long ? term) from the real world, aren't sufficient [53].

ACKNOWLEDGMENT

The authors sincerely acknowledge the support provided by our institution for facilitating this research work. We also thank the faculty members and colleagues who provided valuable guidance and encouragement during the preparation of this article.

REFERENCES

1. Raja, S.N., Carr, D.B., Cohen, M. et al. (2020). The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain, 161, pp.1976–1982. https://doi.org/10.1097/j.pain.0000000000001939.
2. Khera, T. and Rangasamy, V. (2021). Cognition and pain: a review. Frontiers in Psychology, 12, 673962. https://doi.org/10.3389/fpsyg.2021.673962.
3. Hang Kong, A.Y., Tan, H.S. and Habib, A.S. (2024). VX-548 in the treatment of acute pain. Management, 14, pp.477–486. https://doi.org/10.1080/17581869.2024.2421749.
4. Keam, S.J. (2025). Suzetrigine: First approval. Drugs, 85, pp.845–851.
5. Jones, M., Demery, A. and Al-Horani, R.A. (2025). Suzetrigine: A novel non-opioid analgesic for acute pain management—A review. Drugs and Drug Candidates, 4, p.32.
6. Vertex Pharmaceuticals Inc. (2025). Vertex announces FDA approval of Journavx™ (suzetrigine), a first-in-class treatment for adults with moderate to severe acute pain. Media release, 30 January. Available at: https://news.vrtx.com (Accessed: 1 September 2025).
7. Wood, J.N., Yan, N., Huang, J., Zhao, J., Akopian, A., Cox, J.J., Woods, C.G. and Nassar, M.A. (2025). Sensory neuron sodium channels as pain targets; from cocaine to Journavx (VX-548, suzetrigine). Journal of General Physiology, 157, e202513778.
8. Peshin, S., Celi, C.V., Rashid, S., Rego, A. and Baumrucker, S.J. (2025). Pharmacology update: Suzetrigine: a novel NaV1.8 sodium channel inhibitor for acute pain management. American Journal of Hospice and Palliative Medicine.
9. Osteen, J.D., Immani, S., Tapley, T.L., Indersmitten, T., Hurst, N.W., Healey, T., Aertgeerts, K., Negulescu, P.A. and Lechner, S.M. (2025). Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain. Pain and Therapy, 14, pp.655–674.
10. Kaye, A.D., Everett, E.S., Lehuquet, A.M., Mason, J.W., Maitski, R., Plessala, M.J., Barrie, S., Baptiste, C.J., Mychaskiw, G. and Ahmadzadeh, S. (2024). Frontiers in acute pain management: emerging concepts in pain pathways and the role of VX-548 as a novel NaV1.8 inhibitor: a narrative review. Current Pain and Headache Reports, 28, pp.1135–1143.
11. Bennett, D.L., Clark, A.J., Huang, J., Waxman, S.G. and Dib-Hajj, S.D. (2019). The role of voltage-gated sodium channels in pain signaling. Physiological Reviews, 99, pp.1079–1151.
12. Sibomana, O., Okereke, M. and Hakayuwa, C.M. (2025). Suzetrigine approval breaks a 25-year silence: a new era in non-opioid acute pain management. Journal of Pain Research, 18, pp.2805–2808.
13. Wang, H., Huang, J., Zang, J., Jin, X. and Yan, N. (2024). Drug discovery targeting Nav1.8: structural insights and therapeutic potential. Current Opinion in Chemical Biology, 83, 102538.
14. Renganathan, M., Cummins, T.R. and Waxman, S.G. (2001). Contribution of Nav1.8 sodium channels to action potential electrogenesis in DRG neurons. Journal of Neurophysiology, 86, pp.629–640.
15. Blair, N.T. and Bean, B.P. (2003). Role of tetrodotoxin-resistant Na+ current slow inactivation in adaptation of action potential firing in small-diameter dorsal root ganglion neurons. Journal of Neuroscience, 23, p.10338.
16. Majeed, M.H., Ubaidulhaq, M., Rugnath, A. and Eriator, I. (2018). Extreme ends of pain sensitivity in SCN9A mutation variants: case report and literature review. Innovations in Clinical Neuroscience, 15, pp.33–35.
17. Akopian, A.N., Souslova, V., England, S., Okuse, K., Ogata, N., Ure, J., Smith, A., Kerr, B.J., McMahon, S.B. and Boyce, S. (1999). The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nature Neuroscience, 2, pp.541–548.
18. Vaelli, P., Fujita, A., Jo, S., Zhang, H.B., Osorno, T., Ma, X. and Bean, B.P. (2024). State-dependent inhibition of NaV1.8 channels by VX-150 and VX-548. Molecular Pharmacology, 106, pp.298–308.
19. Zeng, X., Powell, R. and Woolf, C.J. (2025). Mechanism-based non-opioid analgesic targets. Journal of Clinical Investigation, 135, e191346.
20. Bertoch, T., D’Aunno, D., McCoun, J., Solanki, D., Taber, L., Urban, J., Oswald, J., Swisher, M.W., Tian, S., Miao, X. et al. (2025) ‘Suzetrigine, a nonopioid NaV1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials’, Anesthesiology, 142, pp. 1085–1099.
21. McCoun, J., Winkle, P., Solanki, D., Urban, J., Bertoch, T., Oswald, J., Swisher, M.W., Taber, L.A., Healey, T., Jazic, I. et al. (2025) ‘Suzetrigine, a non-opioid NaV1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a phase 3 single-arm study for surgical or non-surgical acute pain’, Journal of Pain Research, 18, pp. 1569–1576.
22. Pham, A., Yep, H., Wozniak, S., Javvaji, A., Nada, E. and Bergese, S. (2025) ‘Beyond opioids: a review of suzetrigine for acute pain management’, International Journal of Molecular Sciences, 26, p. 9865. doi:10.3390/ijms26209865.
23. Oliver, B., Devitt, C., Park, G., Razak, A., Liu, S.M. and Bergese, S.D. (2025) ‘Drugs in development to manage acute pain’, Drugs, 85, pp. 11–19. doi:10.1007/s40265-024-02118-0.
24. Yu, G. and Zhou, X. (2024) ‘Gender difference in the pharmacokinetics and metabolism of VX-548 in rats’, Biopharmaceutics and Drug Disposition, 45, pp. 107–114. doi:10.1002/bdd.2387.
25. Zhang, H., Chen, Y., Huang, J. et al. (2024) ‘A simple and sensitive ultra-high performance liquid chromatography tandem mass spectrometry method for the quantitative analysis of VX-548 in monkey plasma: method validation and application to pharmacokinetic study’, Biomedical Chromatography, 38, p. 5907. doi:10.1002/bmc.5907.
26. Human Protein Atlas (2023) SCN10A gene page. [online] Available at: https://www.proteinatlas.org/search/scn10a [Accessed 10 September 2024]
27. Faouzi, A., Varga, B.R. and Majumdar, S. (2020) ‘Biased opioid ligands’, Molecules, 25, p. 4257. doi:10.3390/molecules25184257.
28. Kaye, A.D., Greene, D.R., Nguyen, C. et al. (2024) ‘Emerging medications and strategies in acute pain management: evolving role of novel sodium and calcium channel blockers, peptide-based pharmacologic drugs, and non-medicinal methods’, Current Pain and Headache Reports, 28, pp. 853–862. doi:10.1007/s11916-024-01265-z.
29. Gan, T.J. (2017). Poorly controlled postoperative pain: prevalence, consequences, and prevention. Journal of Pain Research, 10, pp.2287–2298.
30. Friedman, B.W., Abril, L., Naeem, F. et al. (2020). Predicting the transition to chronic pain 6 months after an emergency department visit for acute pain: a prospective cohort study. Journal of Emergency Medicine, 59, pp.805–811.
31. Szewczyk, A.K., Jamroz-Wi?niewska, A., Haratym, N. and Rejdak, K. (2022) ‘Neuropathic pain and chronic pain as an underestimated interdisciplinary problem’, International Journal of Occupational Medicine and Environmental Health, 35, pp. 249–264. doi:10.13075/ijomeh.1896.01676.
32. Kirkpatrick, D.R., McEntire, D.M., Hambsch, Z.J. et al. (2015) ‘Therapeutic basis of clinical pain modulation’, Clinical and Translational Science, 8, pp. 848–856. doi:10.1111/cts.12282.
33. Wheeler, M., Oderda, G.M., Ashburn, M.A. and Lipman, A.G. (2002) ‘Adverse events associated with postoperative opioid analgesia: a systematic review’, Journal of Pain, 3, pp. 159–180. doi:10.1054/jpai.2002.123652.
34. Hu, S., Lyu, D. and Gao, J. (2025). Suzetrigine: the first Nav1.8 inhibitor approved for the treatment of moderate to severe acute pain. Drug Discoveries & Therapeutics, 19, pp.80–82.
35. Stringfellow, E.J., Lim, T.Y., Humphreys, K. et al. (2022). Reducing opioid use disorder and overdose deaths in the United States: a dynamic modeling analysis. Science Advances, 8, eabm8147.
36. Jones, J., Correll, D.J., Lechner, S.M. et al. (2023) ‘Selective inhibition of Na(V)1.8 with VX-548 for acute pain’, New England Journal of Medicine, 389, pp. 393–405. doi:10.1056/NEJMoa2209870.
37. Chen, R., Liu, Y., Qian, L., Yi, M., Yin, H., Wang, S. and Xiang, B. (2025). Sodium channels as a new target for pain treatment. Frontiers in Pharmacology, 16, 1573254.
38. Nikitin, D., Rind, D.M., McQueen, B. et al. (2025). The effectiveness and value of suzetrigine for moderate to severe acute pain: summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council. Journal of Managed Care & Specialty Pharmacy, 31, pp.729–734.
39. Heinle, J.W., Dalessio, S., Janicki, P., Ouyang, A., Vrana, K.E., Ruiz-Velasco, V. and Coates, M.D. (2024) ‘Insights into the voltage gated sodium channel, Na(V)1.8, and its role in visceral pain perception’, Frontiers in Pharmacology, 15, p. 1398409. doi:10.3389/fphar.2024.1398409.
40. Attal, N. and Barrot, M. (2025) ‘Targeting Nav1.8 with the nonopioid antagonist suzetrigine in analgesia: cause for optimism?’, British Journal of Anaesthesia, 11, pp. 7–912. doi:10.1016/j.bja.2025.07.043.
41. Chamessian, A., Payne, M., Gordon, I., Zhou, M. and Gereau, R. (2025) ‘Small molecule-mediated targeted protein degradation of voltage-gated sodium channels involved in pain (Preprint)’, bioRxiv, 2025, p. 4079. doi:10.1101/2025.01.21.634079.
42. Chittoria, K., Sharma, A., Kothari, N. and Kumari, K. (2025) ‘Suzetrigine (VX-548): bidding goodbye to opioids: the latest oral non-opioid analgesic for acute pain’, Saudi Journal of Anaesthesia, 19, pp. 384–386. doi:10.4103/sja.sja_366_25.
43. Mullard, A. (2024) ‘Vertex’s non-opioid painkiller passes phase III tests’, Nature Reviews Drug Discovery, 23, p. 162. doi:10.1038/d41573-024-00029-z.
44. The Medical Letter (2025) ‘Suzetrigine (Journavx) – a sodium channel blocker for acute pain’, Medical Letter on Drugs and Therapeutics, 67, pp. 33–35. doi:10.58347/tml.2025.1723a.
45. FDA (2025) JOURNAVX (suzetrigine) tablets, for oral use. [online] U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219209s000lbl.pdf [Accessed 25 July 2025].
46. Martucci, K.T. (2024) ‘Neuroimaging of opioid effects in humans across conditions of acute administration, chronic pain therapy, and opioid use disorder’, Trends in Neurosciences, 47, pp. 418–431. doi:10.1016/j.tins.2024.04.005.
47. McCoy, D.J., Olson, L.M., Sandson, N.B. and Marcucci, C. (2025) ‘Suzetrigine-Induced Metabolism of Factor Xa Inhibitors May Increase Risk of Thrombosis in Perioperative and Pain Patients’, Anesthesia & Analgesia, 141, e71–e72.
48. Vertex Pharmaceuticals Incorporated (2025) A Phase 3, Open-Label Study Evaluating the Long-Term Safety and Effectiveness of Suzetrigine in Subjects with Pain Associated with Diabetic Peripheral Neuropathy.
49. Vertex Pharmaceuticals Incorporated (2025) A Phase 4, Open-Label, Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine as Part of Multimodal Therapy for Acute Pain After Aesthetic or Reconstructive Surgeries. Available at: https://clinicaltrials.gov/study/NCT06887972 (Accessed: 18 August 2025).
50. Vertex Pharmaceuticals Incorporated (2024) A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Efficacy and Safety of VX-548 in Subjects with Painful Lumbosacral Radiculopathy. Available at: https://clinicaltrials.gov/study/NCT06176196?utm_source=chatgpt.com (clinicaltrials.gov in Bing) (Accessed: 18 August 2025).
51. Mach, M., Giba, A., Miedziaszczyk, M. et al. (2025). Suzetrigine as a novel non-opioid analgesic drug in pain management: a review of clinical evidence and therapeutic perspectives. Cureus, 17(8), e90755. https://doi.org/10.7759/cureus.90755.
52. Srinivasan, S. (2025). Suzetrigine and the future of non-addictive pain management in the midst of the U.S. opioid epidemic. Medtigo Journal of Anesthesiology and Pain Medicine, 1(1), e3067115.
53. Jianguo, C. (2025). Suzetrigine FDA approval: a transformative milestone in pain management. Translational Perioperative and Pain Medicine, 12(1), pp.701–70.